PERK-Selective Kinase Inhibitors (Janssen Pharmaceutica NV)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamePERK-Selective Kinase Inhibitors (Janssen Pharmaceutica NV)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEukaryotic Translation Initiation Factor 2 Alpha Kinase 3 inhibitors
TargetsEukaryotic Translation Initiation Factor 2 Alpha Kinase 3
Therapy Area/IndicationsMultiple MyelomaLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJanssen Pharmaceutica NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Pharmaceutica NV
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A